S'abonner navigation icon
FR
navigation icon menu icon S'abonner
navigation icon Accueil navigation icon Catalogue
icon language Langues navigation icon Menu
icon close
icon arrow

Rechercher

icon searchbar

Rechercher

Catalogue

icon close
icon close
icon close
icon language

Langues

icon close
background image
button download
icon share social
Category Liposomal Daunorubicin Receives Orphan Medicinal Product Designation in European Union for the Treatment of Acute Myeloid Leukaemia
Lire
Lire

Liposomal Daunorubicin Receives Orphan Medicinal Product Designation in European Union for the Treatment of Acute Myeloid Leukaemia

  • 1

    page

  • English

  • Documents

Publié par
icon arrow

  • 1

    page

  • English

  • Documents

Lire
Lire
icon

Description

Liposomal Daunorubicin Receives Orphan Medicinal Product Designation in European Union for the Treatment of Acute Myeloid Leukaemia PR Newswire CRAIGAVON, Northern Ireland, November 15, 2012 CRAIGAVON, Northern Ireland, November 15, 2012 /PRNewswire/ -- Galen announced today that the European Commission has designated liposomal daunorubicin as an orphan
Voir icon arrow
icon success

Ajouté à mes notifications

Vous serez informé des prochaines publications.